Leucine Rich Alpha-2-Glycoprotein 1 Is A Novel Predictor Of Diastolic Dysfunction: A Cross-Sectional Study

Abstract

<jats:title>Abstract</jats:title> <jats:p><jats:bold>Background. </jats:bold>Leucine-rich α2-glycoprotein (LRG1) mediates cardiac fibrocyte activation. It is upregulated in inflammatory conditions, atherosclerosis, and fibrosis. Diastolic dysfunction (DD) is due to myocardial fibrosis. This study examined the relationship between LRG1 and DD. <jats:bold>Methods.</jats:bold> Patients with symptoms of chronic coronary ischemia were recruited. Exclusion criteria: symptoms of overt heart failure, ejection fraction (EF) &lt; 55%, impaired renal function, infection, recent trauma. Investigations: SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) score, Echocardiographic assessment, and LRG1 levels. Binary stepwise logistic regression to evaluate the relationship between LRG1 and DD. ROC analysis with calculation of optimal cut-off values. <jats:bold>Results. </jats:bold>94 patients were included; 47 had diastolic dysfunction. Serum LRG1 was significantly (U = 417.00, p&lt;0.001) higher in the DD group (M=14) compared to the No-DD group (M=8) (U-Mann Whitney Test). There were higher SYNTAX scores in the DD group (M = 24.5) compared with No-DD (M=7). LRG1 had significant predictability of DD (OR =1.30 (95% CI:1.13-1.49)). The ROC for the adjusted model had an AUC=0.89 (95% CI: 0.82-0.95). The cut-off value of “9” LRG1 had a 78% sensitivity (95% CI: 65.3–87.7) and 72.3% specificity (95% CI: 57.4 – 84.4) for predicting DD. <jats:bold>Conclusions.</jats:bold> We identified LRG1 as a novel independent predictor of diastolic dysfunction. Further studies are warranted to validate the utility of LRG1 in predicting DD.</jats:p>